FDA Approves ImClone Systems’ New State-of-the-Art Manufacturing Facility

ImClone Systems Incorporated, a leader in the development and commercialization of novel cancer therapeutics, announced that it has received approval from the Food and Drug Administration for a second facility to manufacture Erbitux.
Imclone